Executive summary

This study reported outcomes of 23 patients with gynecologic malignancies treated with PBSPRT. 12 (52.2%) patients had uterine cancer, 10 (43.5%) cervical, and 1 (4.3%) vaginal.  Median follow up was 4.8 years. 5-year actuarial LC was 95.2%, regional control 90.9%, distant control 74.7% and OS 91.3%. 2 patients (8.7%) had acute G2 GU toxicity, 6 (26.1%) acute GI G2-3 toxicity, and 17 (73.9%) acute G2-4 hematologic toxicity. 3 (13.0%) patients had late G2 GU toxicity, 1 (4.3%) late G2 GI toxicity, 2 (8.7%) late G2-3 hematologic toxicity. 

Key content topics
Top cancer treatments